Drug Profile

Y 08

Alternative Names: Anti-IL-1RAP monoclonal antibody - U mab Biopharma; Y-08

Latest Information Update: 18 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator U-mab Biopharma
Developer Shanghai Henlius Biotech; U-mab Biopharma
Class Anti-inflammatories; Immunotherapies; Monoclonal antibodies
Mechanism of Action Interleukin-1 receptor accessory protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Autoimmune disorders; Inflammation

Most Recent Events

14 Jan 2026 Shanghai Henlius Biotech enters into an exclusive global license agreement with U-mab Biopharma for Autoimmune disorders and Inflammation
14 Jan 2026 U mab Biopharma has patent protection for Anti-IL-1RAP monoclonal antibody
14 Jan 2026 Preclinical trials in Autoimmune disorders in China (Parenteral)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com